Alembic Pharma Share Price: USFDA Se Mili Parkinson's Drug Ki Approval! Ab Kya Hoga?

HEALTHCAREBIOTECH
Whalesbook Logo
AuthorIshaan Verma|Published at:
Alembic Pharma Share Price: USFDA Se Mili Parkinson's Drug Ki Approval! Ab Kya Hoga?
Overview

Chalo, pharma stocks ki duniya se ek badi khabar! Alembic Pharmaceuticals ko USFDA se Parkinson's disease ki ek important generic drug - Carbidopa, Levodopa, aur Entacapone tablets - ke liye approval mil gaya hai. Yeh approval company ke liye US market mein entry ka ek naya raasta kholta hai.

Parkinson's Ka Naya Generic Player!

USFDA ne finally Alembic Pharma ko Parkinson's ki dawa, Carbidopa, Levodopa, aur Entacapone ke generic version ke liye green signal de diya hai. Ye approval 6 different strengths mein aaya hai, jo Orion Corporation ki Stalevo tablets ke jaisi hi hain. Socho, ab Parkinson's patients ke liye cost-effective option mil sakta hai.

US mein generic drugs ka market already $96.78 billion ka hai aur 2034 tak $129.2 billion tak pahunchne ka andaaza hai. Aur CNS (Central Nervous System) drugs, jisme Parkinson's treatments aate hain, woh is market ka bada hissa hain. Toh, Alembic ke liye ye ekdum sahi time hai US mein apni jagah banane ka.

Company Ki Financial Situation Kya Bolti Hai?

Ab jab approval mil gaya hai, toh company ki financial health dekhna bhi zaroori hai. Alembic Pharma ka P/E ratio 24.7x se 28.1x ke beech chal raha hai aur market cap lagbhag ₹15,692 crore hai. Stock ne pichhle ek saal mein -9.16% ka return diya hai, matlab thoda neeche hi raha hai, ₹725.20 se ₹1,107.90 ke range mein.

Aur haan, market mein kuch tension bhi hai. November 2025 mein analysts ne Alembic ko 'Sell' rating di thi, matlab unko future mein thodi problems dikh rahi hain. Pichhle 5 saalon mein company ki sales growth bhi 7.69% hi rahi hai aur margins par bhi pressure hai. Par latest Q2 FY'26 mein company ne 16% YoY growth dikhaya hai, jo ek achhi baat hai. Dekhna hoga ki ye Parkinson's drug unke revenue mein kitna boost laata hai, especially jab Stalevo toh 2003 se market mein hai.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.